Arch Biopartners has identified a new drug candidate to treat Pseudomonas aeruginosa respiratory infections and intends to move forward with a human trial this year to test its safety.
Arch management believes this new drug has the potential to be a major break through in the treatment of P. aeruginosa respiratory infections. During the upcoming year, Arch is intending to move forward with a human trial to test the safety and efficacy of the new drug against P. aeruginosa respiratory infections in cystic fibrosis patients.
Arch has entered into a one year option agreement with UC to exclusively license the commercial rights to a pending U.S. Patent for the new drug treatment. Arch and UC have also extended for another year the existing option to license the commercial rights to a related U.S. Patent for treating bacterial respiratory infections using acidified nitrite.